Acute promyelocytic leukemia historical perspective: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
Line 9: | Line 9: | ||
*In the '''early 1990s''', it was noted that arsenic trioxide could induce remission in a high proportion of patients.<ref name="pmid25885425">{{cite journal| author=Coombs CC, Tavakkoli M, Tallman MS| title=Acute promyelocytic leukemia: where did we start, where are we now, and the future. | journal=Blood Cancer J | year= 2015 | volume= 5 | issue= | pages= e304 | pmid=25885425 | doi=10.1038/bcj.2015.25 | pmc=4450325 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25885425 }} </ref> | *In the '''early 1990s''', it was noted that arsenic trioxide could induce remission in a high proportion of patients.<ref name="pmid25885425">{{cite journal| author=Coombs CC, Tavakkoli M, Tallman MS| title=Acute promyelocytic leukemia: where did we start, where are we now, and the future. | journal=Blood Cancer J | year= 2015 | volume= 5 | issue= | pages= e304 | pmid=25885425 | doi=10.1038/bcj.2015.25 | pmc=4450325 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25885425 }} </ref> | ||
*In '''1995''', D. Head and colleagues showed that higher remission rates and higher survival rates could be achieved with higher doses of [[daunorubicin]], with a survival rate of 61% after 9 years and a 0% relapse after 36 months.<ref name="pmid7655004">{{cite journal| author=Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K et al.| title=Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. | journal=Blood | year= 1995 | volume= 86 | issue= 5 | pages= 1717-28 | pmid=7655004 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7655004 }} </ref> | *In '''1995''', D. Head and colleagues showed that higher remission rates and higher survival rates could be achieved with higher doses of [[daunorubicin]], with a survival rate of 61% after 9 years and a 0% relapse after 36 months.<ref name="pmid7655004">{{cite journal| author=Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K et al.| title=Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. | journal=Blood | year= 1995 | volume= 86 | issue= 5 | pages= 1717-28 | pmid=7655004 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7655004 }} </ref> | ||
*In '''2013''', LoCoco and colleagues showed that, in a randomized phase 3 multicenter clinical trial, a non-chemotherapy-based regimen was superior to a chemotherapy-based regimen for low-risk acute promyelocytic leukemia.<ref name="pmid23841729">{{cite journal| author=Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al.| title=Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. | journal=N Engl J Med | year= 2013 | volume= 369 | issue= 2 | pages= 111-21 | pmid=23841729 | doi=10.1056/NEJMoa1300874 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23841729 }} </ref> Specifically, the combination of all-''trans'' retinoic acid and arsenic trioxide resulted in improved overall survival compared to the combination of all-''trans'' retinoic acid plus chemotherapy. This landmark clinical trial, which was conducted by the Italian and German-Austrian Leukemia Study Groups, altered the treatment paradigm for low-risk acute promyelocytic leukemia.<ref name="pmid23841729">{{cite journal| author=Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al.| title=Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. | journal=N Engl J Med | year= 2013 | volume= 369 | issue= 2 | pages= 111-21 | pmid=23841729 | doi=10.1056/NEJMoa1300874 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23841729 }} </ref> | |||
==References== | ==References== |
Revision as of 17:37, 29 April 2018
Acute promyelocytic leukemia Microchapters |
Differentiating Acute promyelocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acute promyelocytic leukemia historical perspective On the Web |
American Roentgen Ray Society Images of Acute promyelocytic leukemia historical perspective |
Acute promyelocytic leukemia historical perspective in the news |
Blogs on Acute promyelocytic leukemia historical perspective |
Directions to Hospitals Treating Acute promyelocytic leukemia |
Risk calculators and risk factors for Acute promyelocytic leukemia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Historical perspective
- In 1957, acute promyelocytic leukemia was described as a distinct clinical condition for the first time. It was noted that this condition carried a high mortality rate due to severe hemorrhage.[1]
- In 1973, clinical studies showed the therapeutic efficacy of daunorubicin, an chemotherapy agent of the anthracycline class. This medication was shown to induce remission in the majority of patients, with an increase in remission rate from 13% to 58%. The median duration of remission with daunorubicin was more than 2 years. Compared to 6-mercaptopurine, daunorubicin was shown to reduce mortality from bleeding after 5 days.[1]
- In the early 1990s, it was noted that arsenic trioxide could induce remission in a high proportion of patients.[1]
- In 1995, D. Head and colleagues showed that higher remission rates and higher survival rates could be achieved with higher doses of daunorubicin, with a survival rate of 61% after 9 years and a 0% relapse after 36 months.[2]
- In 2013, LoCoco and colleagues showed that, in a randomized phase 3 multicenter clinical trial, a non-chemotherapy-based regimen was superior to a chemotherapy-based regimen for low-risk acute promyelocytic leukemia.[3] Specifically, the combination of all-trans retinoic acid and arsenic trioxide resulted in improved overall survival compared to the combination of all-trans retinoic acid plus chemotherapy. This landmark clinical trial, which was conducted by the Italian and German-Austrian Leukemia Study Groups, altered the treatment paradigm for low-risk acute promyelocytic leukemia.[3]
References
- ↑ 1.0 1.1 1.2 Coombs CC, Tavakkoli M, Tallman MS (2015). "Acute promyelocytic leukemia: where did we start, where are we now, and the future". Blood Cancer J. 5: e304. doi:10.1038/bcj.2015.25. PMC 4450325. PMID 25885425.
- ↑ Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K; et al. (1995). "Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia". Blood. 86 (5): 1717–28. PMID 7655004.
- ↑ 3.0 3.1 Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S; et al. (2013). "Retinoic acid and arsenic trioxide for acute promyelocytic leukemia". N Engl J Med. 369 (2): 111–21. doi:10.1056/NEJMoa1300874. PMID 23841729.